by GlobeNewsWire | Aug 12, 2016 | Globe Newswire
RAMSEY, N.J., Aug. 12, 2016 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the proposed treatment of immune deficiencies...
by GlobeNewsWire | Jul 29, 2016 | Globe Newswire
RAMSEY, N.J., July 29, 2016 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the proposed treatment of immune deficiencies...
by GlobeNewsWire | Jul 26, 2016 | Globe Newswire
Focus on Cost Improvement and Project Execution Results in Significant Operating Margin Improvements Pemex Abkatun-A2 Award Demonstrates Vertically Integrated, Local Solution in MexicoExtensive Experience in Middle East Leads to Large EPCI Awards Driving Substantial...
by GlobeNewsWire | May 13, 2016 | Globe Newswire
RAMSEY, N.J., May 13, 2016 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain...
by GlobeNewsWire | May 3, 2016 | Globe Newswire
RAMSEY, N.J., May 03, 2016 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain...